EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma
- PMID: 20006402
- DOI: 10.1016/j.jhep.2009.10.026
EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma
Abstract
Background & aims: Cancer progression/metastases and embryonic development share many properties including cellular plasticity, dynamic cell motility, and integral interaction with the microenvironment. We hypothesized that the heterogeneous nature of hepatocellular carcinoma (HCC), in part, may be owing to the presence of hepatic cancer cells with stem/progenitor features.
Methods: Gene expression profiling and immunohistochemistry analyses were used to analyze 235 tumor specimens derived from 2 recently identified HCC subtypes (EpCAM(+) alpha-fetoprotein [AFP(+)] HCC and EpCAM(-) AFP(-) HCC). These subtypes differed in their expression of AFP, a molecule produced in the developing embryo, and EpCAM, a cell surface hepatic stem cell marker. Fluorescence-activated cell sorting was used to isolate EpCAM(+) HCC cells, which were tested for hepatic stem/progenitor cell properties.
Results: Gene expression and pathway analyses revealed that the EpCAM(+) AFP(+) HCC subtype had features of hepatic stem/progenitor cells. Indeed, the fluorescence-activated cell sorting-isolated EpCAM(+) HCC cells displayed hepatic cancer stem cell-like traits including the abilities to self-renew and differentiate. Moreover, these cells were capable of initiating highly invasive HCC in nonobese diabetic, severe combined immunodeficient mice. Activation of Wnt/beta-catenin signaling enriched the EpCAM(+) cell population, whereas RNA interference-based blockage of EpCAM, a Wnt/beta-catenin signaling target, attenuated the activities of these cells.
Conclusions: Taken together, our results suggest that HCC growth and invasiveness is dictated by a subset of EpCAM(+) cells, opening a new avenue for HCC cancer cell eradication by targeting Wnt/beta-catenin signaling components such as EpCAM.
Similar articles
-
EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features.Gastroenterology. 2009 Mar;136(3):1012-24. doi: 10.1053/j.gastro.2008.12.004. Epub 2008 Dec 6. Gastroenterology. 2009. PMID: 19150350 Free PMC article.
-
EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma.Cancer Res. 2008 Mar 1;68(5):1451-61. doi: 10.1158/0008-5472.CAN-07-6013. Cancer Res. 2008. PMID: 18316609
-
High expression of MAGE-A9 contributes to stemness and malignancy of human hepatocellular carcinoma.Int J Oncol. 2018 Jan;52(1):219-230. doi: 10.3892/ijo.2017.4198. Epub 2017 Nov 9. Int J Oncol. 2018. PMID: 29138811
-
Relevant markers of cancer stem cells indicate a poor prognosis in hepatocellular carcinoma patients: a meta-analysis.Eur J Gastroenterol Hepatol. 2013 Sep;25(9):1007-16. doi: 10.1097/MEG.0b013e32836019d8. Eur J Gastroenterol Hepatol. 2013. PMID: 23478672 Review.
-
EpCAM and its potential role in tumor-initiating cells.Cell Adh Migr. 2012 Jan-Feb;6(1):30-8. doi: 10.4161/cam.18953. Cell Adh Migr. 2012. PMID: 22647938 Free PMC article. Review.
Cited by
-
Upregulated microRNA-92b regulates the differentiation and proliferation of EpCAM-positive fetal liver cells by targeting C/EBPß.PLoS One. 2013 Aug 2;8(8):e68004. doi: 10.1371/journal.pone.0068004. Print 2013. PLoS One. 2013. PMID: 23936298 Free PMC article.
-
EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1.J Immunother Cancer. 2020 Mar;8(1):e000301. doi: 10.1136/jitc-2019-000301. J Immunother Cancer. 2020. PMID: 32221015 Free PMC article.
-
Cancer stemness in hepatocellular carcinoma: mechanisms and translational potential.Br J Cancer. 2020 May;122(10):1428-1440. doi: 10.1038/s41416-020-0823-9. Epub 2020 Mar 31. Br J Cancer. 2020. PMID: 32231294 Free PMC article. Review.
-
Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery.Theranostics. 2017 Sep 20;7(17):4071-4086. doi: 10.7150/thno.20168. eCollection 2017. Theranostics. 2017. PMID: 29158811 Free PMC article.
-
Immunotherapy for advanced or recurrent hepatocellular carcinoma.World J Gastrointest Oncol. 2023 Mar 15;15(3):405-424. doi: 10.4251/wjgo.v15.i3.405. World J Gastrointest Oncol. 2023. PMID: 37009314 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous